A composition comprising a novel Ca2+-activated [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion which causes severe cell depolarization followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by su...

A method for preparing a tolbutamide particle is provided. The method comprises steps of mixing a bulk drug of tolbutamide with a supercritical fluid to form a supercritical mixture

A method for preparing a tolbutamide particle is provided. The method comprises steps of mixing a bulk drug of tolbutamide with a supercritical fluid to form a supercritical mixture; and expanding the supercritical mixture to obtain the tolbutamide particle.

A process for making an oral dosage form of a pharmaceutical composition comprising the steps of: (a) combining a therapeutic compound selected from the group consisting of metoclopramide and propantheline bromide

The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intra-venous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide tolbutamide repaglinide nateglinide meglitinide midaglizole LY397364 LY389382 glyclazide and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g. dilution of 1:1 or 1:1.2) suitable for bolus injections and may be further dilut...

A tolbutamide microparticle and its preparation method and use are provided. The tolbutamide microparticle having increasing pharmaceutical usefulness is obtained by the application of a supercritical fluid.

NSC antagonists are disclosed as useful in the treatment of dementia in delaying the onset of dementia and in the prevention of dementia. Dementia so treated may be for example Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone a) in combination with other drugs used for treating dementia b) in combination with drugs that stabilize or increase blood plasma glucose levels or with both a) and b). Pharmaceutical compositions dosage forms and methods...

NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, an...

The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intravenous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide tolbutamide repaglinide nateglinide meglitinide midaglizole LY397364 LY389382 glyclazide and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g. dilution of 1 : 1 or 1 : 1.2) suitable for bolus injections and may be further di...